Dealmaking on a Small Planet: Medical Device Transactions 2001
Dealmaking in the device industry is occasional and incremental when compared with the level of activity in pharmaceuticals, the result of that industry's maturing into a handful of dominant players, not all of which see acquisitions as strategically critical to their long-term success. The less-than-robust public market for small device companies is both symptom and cause of the device dealmaking lull. Because the markets they target are generally too small to sustain years of significant growth, few investors are willing to invest in them as stand-alone companies. And without long-term investor support, smaller firms have few options other than to sell out to large companies and little negotiating leverage when they do so.
To better understand medical device dealmaking as it has evolved
over the past two years, one need only compare it to the activity
in pharmaceuticals. In the medical device industry, which has
matured into a handful of utterly dominant players, dealmaking is
occasional and incremental; in the pharmaceutical business, which
is in strategic, tactical, and scientific turmoil, it is constant
and frequently transforming.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.
During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
